Annual EBITDA
-$31.35 M
-$3.67 M-13.26%
December 31, 2023
Summary
- As of February 8, 2025, ATOS annual EBITDA is -$31.35 million, with the most recent change of -$3.67 million (-13.26%) on December 31, 2023.
- During the last 3 years, ATOS annual EBITDA has fallen by -$16.79 million (-115.34%).
- ATOS annual EBITDA is now -2809.88% below its all-time high of -$1.08 million, reached on December 31, 2010.
Performance
ATOS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$6.38 M
+$720.00 K+10.14%
September 30, 2024
Summary
- As of February 8, 2025, ATOS quarterly EBITDA is -$6.38 million, with the most recent change of +$720.00 thousand (+10.14%) on September 30, 2024.
- Over the past year, ATOS quarterly EBITDA has increased by +$1.08 million (+14.52%).
- ATOS quarterly EBITDA is now -6790.93% below its all-time high of -$92.60 thousand, reached on September 30, 2009.
Performance
ATOS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$29.46 M
+$1.08 M+3.55%
September 30, 2024
Summary
- As of February 8, 2025, ATOS TTM EBITDA is -$29.46 million, with the most recent change of +$1.08 million (+3.55%) on September 30, 2024.
- Over the past year, ATOS TTM EBITDA has increased by +$1.02 million (+3.36%).
- ATOS TTM EBITDA is now -31716.41% below its all-time high of -$92.60 thousand, reached on September 30, 2009.
Performance
ATOS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ATOS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -13.3% | +14.5% | +3.4% |
| 3 y3 years | -115.3% | -23.9% | -48.1% |
| 5 y5 years | -175.3% | -23.9% | -48.1% |
ATOS EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -53.0% | at low | -34.5% | +29.1% | -43.7% | +6.0% |
| 5 y | 5-year | -115.3% | at low | -145.0% | +29.1% | -131.3% | +6.0% |
| alltime | all time | -2809.9% | at low | -6790.9% | +29.1% | <-9999.0% | +6.0% |
Atossa Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$6.38 M(-10.1%) | -$29.46 M(-3.5%) |
| Jun 2024 | - | -$7.10 M(+1.8%) | -$30.55 M(-2.2%) |
| Mar 2024 | - | -$6.97 M(-22.5%) | -$31.23 M(-0.4%) |
| Dec 2023 | -$31.35 M(+13.3%) | -$9.01 M(+20.6%) | -$31.36 M(+2.9%) |
| Sep 2023 | - | -$7.46 M(-4.2%) | -$30.49 M(-2.4%) |
| Jun 2023 | - | -$7.79 M(+9.8%) | -$31.22 M(+4.0%) |
| Mar 2023 | - | -$7.09 M(-12.8%) | -$30.03 M(+8.5%) |
| Dec 2022 | -$27.68 M(+35.1%) | -$8.14 M(-0.8%) | -$27.68 M(+13.6%) |
| Sep 2022 | - | -$8.20 M(+24.4%) | -$24.37 M(+14.3%) |
| Jun 2022 | - | -$6.59 M(+38.9%) | -$21.32 M(-1.9%) |
| Mar 2022 | - | -$4.75 M(-1.7%) | -$21.72 M(+6.0%) |
| Dec 2021 | -$20.50 M(+40.8%) | -$4.83 M(-6.3%) | -$20.50 M(+3.1%) |
| Sep 2021 | - | -$5.15 M(-26.4%) | -$19.89 M(+9.1%) |
| Jun 2021 | - | -$7.00 M(+98.7%) | -$18.23 M(+20.3%) |
| Mar 2021 | - | -$3.52 M(-16.5%) | -$15.16 M(+4.1%) |
| Dec 2020 | -$14.56 M(-15.4%) | -$4.22 M(+20.6%) | -$14.56 M(+12.4%) |
| Sep 2020 | - | -$3.50 M(-10.9%) | -$12.95 M(+1.7%) |
| Jun 2020 | - | -$3.92 M(+34.1%) | -$12.74 M(-20.8%) |
| Mar 2020 | - | -$2.92 M(+12.3%) | -$16.09 M(-6.5%) |
| Dec 2019 | -$17.21 M(+51.1%) | -$2.60 M(-20.7%) | -$17.21 M(+3.1%) |
| Sep 2019 | - | -$3.29 M(-54.8%) | -$16.70 M(-0.1%) |
| Jun 2019 | - | -$7.27 M(+79.6%) | -$16.71 M(+23.1%) |
| Mar 2019 | - | -$4.05 M(+93.6%) | -$13.57 M(+19.2%) |
| Dec 2018 | -$11.39 M(+61.4%) | -$2.09 M(-36.6%) | -$11.39 M(+5.4%) |
| Sep 2018 | - | -$3.30 M(-20.2%) | -$10.80 M(+13.3%) |
| Jun 2018 | - | -$4.13 M(+121.4%) | -$9.53 M(+31.3%) |
| Mar 2018 | - | -$1.87 M(+24.0%) | -$7.26 M(+2.9%) |
| Dec 2017 | -$7.06 M | -$1.50 M(-25.8%) | -$7.06 M(-3.1%) |
| Sep 2017 | - | -$2.03 M(+8.8%) | -$7.28 M(+8.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2017 | - | -$1.86 M(+12.0%) | -$6.74 M(+3.3%) |
| Mar 2017 | - | -$1.66 M(-3.8%) | -$6.52 M(-8.3%) |
| Dec 2016 | -$6.95 M(-44.4%) | -$1.73 M(+16.5%) | -$7.11 M(-8.3%) |
| Sep 2016 | - | -$1.48 M(-9.8%) | -$7.75 M(-22.5%) |
| Jun 2016 | - | -$1.65 M(-26.9%) | -$10.00 M(-13.2%) |
| Mar 2016 | - | -$2.25 M(-5.0%) | -$11.52 M(-7.7%) |
| Dec 2015 | -$12.49 M(+33.7%) | -$2.37 M(-36.5%) | -$12.48 M(+13.6%) |
| Sep 2015 | - | -$3.73 M(+17.6%) | -$10.98 M(+5.9%) |
| Jun 2015 | - | -$3.17 M(-1.2%) | -$10.37 M(+1.1%) |
| Mar 2015 | - | -$3.21 M(+266.1%) | -$10.26 M(+9.9%) |
| Dec 2014 | -$9.34 M(-9.4%) | -$876.40 K(-71.9%) | -$9.34 M(-15.9%) |
| Sep 2014 | - | -$3.12 M(+1.9%) | -$11.10 M(-2.3%) |
| Jun 2014 | - | -$3.06 M(+33.8%) | -$11.36 M(+5.6%) |
| Mar 2014 | - | -$2.29 M(-13.3%) | -$10.75 M(+4.3%) |
| Dec 2013 | -$10.31 M(+108.8%) | -$2.64 M(-22.0%) | -$10.31 M(+11.2%) |
| Sep 2013 | - | -$3.38 M(+37.6%) | -$9.28 M(+32.0%) |
| Jun 2013 | - | -$2.46 M(+33.3%) | -$7.03 M(+22.7%) |
| Mar 2013 | - | -$1.84 M(+15.1%) | -$5.73 M(+16.0%) |
| Dec 2012 | -$4.94 M(+44.8%) | -$1.60 M(+42.0%) | -$4.94 M(+9.1%) |
| Sep 2012 | - | -$1.13 M(-2.6%) | -$4.52 M(-3.0%) |
| Jun 2012 | - | -$1.16 M(+9.9%) | -$4.66 M(+9.4%) |
| Mar 2012 | - | -$1.05 M(-11.3%) | -$4.26 M(+24.1%) |
| Dec 2011 | -$3.41 M(+216.4%) | -$1.19 M(-6.3%) | -$3.43 M(+32.8%) |
| Sep 2011 | - | -$1.27 M(+67.6%) | -$2.59 M(+43.9%) |
| Jun 2011 | - | -$755.70 K(+235.3%) | -$1.80 M(+45.1%) |
| Mar 2011 | - | -$225.40 K(-33.4%) | -$1.24 M(+22.3%) |
| Dec 2010 | -$1.08 M | -$338.40 K(-29.1%) | -$1.01 M(+50.2%) |
| Sep 2010 | - | -$477.30 K(+142.0%) | -$674.50 K(+132.7%) |
| Jun 2010 | - | -$197.20 K(+113.0%) | -$289.80 K(+213.0%) |
| Sep 2009 | - | -$92.60 K | -$92.60 K |
FAQ
- What is Atossa Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Atossa Therapeutics?
- What is Atossa Therapeutics annual EBITDA year-on-year change?
- What is Atossa Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Atossa Therapeutics?
- What is Atossa Therapeutics quarterly EBITDA year-on-year change?
- What is Atossa Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Atossa Therapeutics?
- What is Atossa Therapeutics TTM EBITDA year-on-year change?
What is Atossa Therapeutics annual EBITDA?
The current annual EBITDA of ATOS is -$31.35 M
What is the all time high annual EBITDA for Atossa Therapeutics?
Atossa Therapeutics all-time high annual EBITDA is -$1.08 M
What is Atossa Therapeutics annual EBITDA year-on-year change?
Over the past year, ATOS annual EBITDA has changed by -$3.67 M (-13.26%)
What is Atossa Therapeutics quarterly EBITDA?
The current quarterly EBITDA of ATOS is -$6.38 M
What is the all time high quarterly EBITDA for Atossa Therapeutics?
Atossa Therapeutics all-time high quarterly EBITDA is -$92.60 K
What is Atossa Therapeutics quarterly EBITDA year-on-year change?
Over the past year, ATOS quarterly EBITDA has changed by +$1.08 M (+14.52%)
What is Atossa Therapeutics TTM EBITDA?
The current TTM EBITDA of ATOS is -$29.46 M
What is the all time high TTM EBITDA for Atossa Therapeutics?
Atossa Therapeutics all-time high TTM EBITDA is -$92.60 K
What is Atossa Therapeutics TTM EBITDA year-on-year change?
Over the past year, ATOS TTM EBITDA has changed by +$1.02 M (+3.36%)